Functional Evaluation of Two Types of Totally Implanted Venous Ports

Status Completed

Clinical Trial Summary

Totally implanted venous access ports allow a safe delivery of medication, mainly chemotherapy, but are also used for blood sampling. This last procedure is not always successful, as it appeared from a nurse's survey in different hospitals in Flanders, including the University Hospitals in Leuven, Belgium. In 3 to 29 percent of the attempts, blood withdrawal is impaired or not possible, as an intermittent or permanent fact. This is in line with international literature data where difficulty in blood draw was noted in 6 to 26% of port accessions. Partial or total occlusion leads to discomfort for the patient, delay in therapy, higher costs and extra nursing time.

A new port system with a tangential outlet (Vortex port) was designed and according to the manufacturer, this shape will allow to cleanse the entire reservoir of the port more efficiently and avoid the formation of precipitates of medication or blood that could lead to an obstruction of the device. These precipitates are also regarded as a potential risk factor for infection.

However, only one previously published small randomised study addressed the value of the Vortex port when compared to conventional access devices: Stevens et al. were able to show a reduction in obstruction incidence from 26% to 7% with the use of the Vortex port. The incidence of blood withdrawal problems in our experience with conventional ports in University hospitals Leuven was 8% thus lower than that reported by Stevens, but this remains the most frequent problem faced by care providers and patients.

With this study, the investigators aim to compare the performance of the tangential outlet ports and that of a "conventional" port in order to assess an eventual functional difference.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00484848
Study type	Interventional
Source	Universitaire Ziekenhuizen Leuven
Contact
Status	Completed
Phase	N/A
Start date	September 2004
Completion date	March 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00507533` - Early Application of CPAP in Hematologic	Phase 4
Completed	`NCT00168090` - Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)	Phase 4
Recruiting	`NCT03920735` - Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
Completed	`NCT00001749` - Medical Treatment for Diamond Blackfan Anemia	Phase 2
Completed	`NCT03013439` - Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)	Phase 1
Completed	`NCT00994136` - Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters	Phase 4
Completed	`NCT01178177` - Radiologic Features of Invasive Pulmonary Aspergillosis	N/A
Completed	`NCT00111215` - Treatment and Management of Women With Bleeding Disorders	N/A
Completed	`NCT00586521` - BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)	Phase 4
Completed	`NCT00782470` - Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A	N/A
Completed	`NCT00001715` - Evaluation of Patients With Blood Disorders
Completed	`NCT01426295` - Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital	Phase 2
Completed	`NCT01220011` - Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.